Former Detroit Lions wide receiver Calvin Johnson and his business partner, ex-NFL lineman Rob Sims, have partnered with Harvard University to research the benefits of medical marijuana in the areas of Chronic Traumatic Encephalopathy, more commonly known as CTE, as well as the management of pain.
The duo — who co-own the cannabis company Primative — announced the partnership, which includes a six-figure donation with the option for future money given to the International Phytomedicines and Medical Cannabis Institute at Harvard during the Cannabis Capital Conference in Detroit on Thursday.
“We can be in position to develop a treatment for CTE,” Sims told ESPN on Thursday night. “There’s been suggestion that CBD and stuff can help cognitive disease and we think that potentially there could be a treatment going forward that we can produce.”
Sims and Johnson were part of Harvard’s Global Catalyst Health Summit in May, when they agreed to make the commitment to give research money and start a consortium with the brain performance company NESTRE to work with the Institute and Dr. Wilfred Ngwa. NESTRE has worked with NFL athletes on brain training, including former quarterback and current ESPN analyst Josh McCown later in his career.
As part of the partnership, Harvard will do medical research for Primative, run clinical trials related to CTE and pain and also will provide quality assurance from the Harvard Medical School for any products the company creates. As former NFL players, Sims and Johnson researched studies on CTE and football that show a prevalence of former players having the disease, which can only be diagnosed postmortem.
“As being former athletes, we know there’s some sort of CTE or some sort of damage, 99 percent I think they say in the study,” Sims said. “So that means I may be walking around with some form of it. It’s really about the hope. Just providing hope, improving the game, making the game safer for former players after they are done.
“Really just being able to help people. I’m a second-generation NFL kid, both my father and father-in-law. I’ve seen the good, the bad and the ugly of what it looks like when you’re done playing ball. If we can help this facet of people suffering from CTE or other cognitive disease, that’s the real goal here.”
This is the beginning of what Johnson and Sims are hoping is a long-term partnership with the Institute. If they are able to help people, they figure the business portion of it will follow after.
“What our mission is going to be is just to improve quality of life,” Sims said. “So, you know, with NESTRE and the brain training and the human optimization, we believe there’s a way to continue to improve your brain function through working out.
“Then from our position, with that data that we’ll be able to gain, we believe that we can produce plant medicines, or cannabis, using nanotechnology to deliver payloads to areas where people would have symptoms of CTE, like mood and anxiety and memory loss. That’s the goal in the end.”
Sims said there isn’t a set date for the clinical trials to begin, but he is hopeful they can start during the first quarter of 2020.
This is the latest business venture for Sims and Johnson, who started working as a real estate company and then also opened a consulting firm before choosing to go the cannabis route after Michigan legalized marijuana last November. Their first attempt to get a license was rejected by the state — and those issues have since been rectified and their first cultivation facility is scheduled to open within the next month or so in Webberville, Mich.
That’s a long way from their beginnings, when they never imagined they would be partnered with Harvard.
“Never in a million years, man,” Sims said. “I was trying to get Calvin to flip one or two houses with me two years ago, and then we ended up getting into cannabis real estate, and then we ended up getting into the licensing part of it, and now we’re getting into the medicine part of it.
“So it’s been quite a journey and I’m just looking forward to the future.”